Study Duration Sample Clauses

Study Duration. The Study is expected to be initiated from to .

Study Duration. The Parties anticipate that the Study will be conducted during the period commencing on the Effective Date and ending on or prior to the fifth anniversary thereof. Sponsor will communicate any changes to the foregoing timeline to Site in writing. (b)

Study Duration. For subjects, the study will consist of a Screening period of up to 30 days (can be extended in certain circumstances see Section 5.2.1), with randomisation at the Treatment Visit (Day 1) up to 14 days later (can be extended if UTI prevents IMP administration - see Section 5.2.3). Follow-up for each subject is planned to be 24 months (104 weeks) after the first IMP administration. However, as retreatments can occur up to Week 104, and 12 weeks of follow- up will occur following each study retreatment, the maximum planned subject participation following randomisation is 116 weeks. Each subject's participatiou iu the study will be considered to have ended at the time of their last study visit, including follow-up for AEs after the last IMP administration: • CCI The study will be considered to have started when the first subject has provided signed informed consent and to have ended after the last subject has completed their last study visit.

Study Duration. Institution will make every effort to complete the study within 15 months. Institution will recruit no less than seven sites if needed to conduct the study within the 15 month period. 5. Change Orders.

Study Duration. Objectives of the Study: Study Endpoints: (Primary and Secondary) Study Design: Eligibility Criteria (Inclusion and Exclusion) Study Procedures: (Including pharmacokinetic (PK) sampling times) Safety Parameters/analysis: Laboratory Parameters/Analysis: Total Blood Volume: Sample Size Determination: (If applicable) Statistical Analyses: (Brief Description) Others : (As required by the specific study)

Study Duration. It is anticipated that the Clinical Study will commence upon execution of this Agreement, that subject enrollment will be completed approximately in four months from the date of Site Initiation Visit, and that the Clinical Study will be completed as per the study schedule, unless otherwise terminated in accordance with Section 7.

Study Duration. For each subject, the total study duration is expected to be approximately 20 weeks as follows: Screening period: 4 weeks Treatment period: 12 weeks Follow-up period 4 weeks from last dose of study treatment

Study Duration. Patients will participate in the study for up to ~34 weeks, inclusive of the Screening, Pain Observation, double-blind, placebo-controlled Treatment, open label Safety Extension, and washout Follow-up periods. During the Pain Observation period, patients will be dosed daily with placebo under single-blind conditions. During the approximately 12-week double-blind, placebo-controlled Treatment period, patients will be dosed daily with ricolinostat or placebo under double-blind conditions. During the approximately 12-week open-label Safety Extension, all patients will receive ricolinostat.‌‌‌‌‌‌

Study Duration. ‌ Approximately 41 months (176 weeks)